52 completed, 13 unknown, 10 terminated, 7 active not recruiting. 45 Phase 3, 27 Phase 2, 4 Not applicable, 4 Phase 1.
By phase and status
Phase Trials Status Phase 3 45 Completed 27 , Terminated 8 , Active not recruiting 5 , Unknown 4 , Recruiting 1 Phase 2 27 Completed 17 , Withdrawn 4 , Unknown 3 , Terminated 2 , Recruiting 1 Not applicable 4 Completed 3 , Active not recruiting 1 Phase 1 4 Completed 2 , Unknown 1 , Withdrawn 1
Follow NSABP Foundation Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) Cemiplimab, cemiplimab plus fianlimab, cemiplimab + REGN7075 - Colo-rectal Cancer Phase 2 Recruiting NSABP Foundation Inc 79 2026-04-17 2026-09-03 EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) ctDNA MRD test - Breast Cancer Recruiting Exact Sciences Corporation 1800 2024-06-07 2026-01-20 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine - Triple Negative Breast Cancer Phase 3 Recruiting Gilead Sciences 1514 2022-12-12 2026-10-13 A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy Gevokizumab, Signatera test - Colon Cancer Phase 2 Withdrawn NSABP Foundation Inc 2022-06-24 2022-11-04 CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer MRD - Colorectal Cancer Active not recruiting Exact Sciences Corporation 1017 2021-12-15 2026-01-12 A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) DS-8201a, T-DM1 - HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer Phase 3 Active not recruiting Daiichi Sankyo 1600 2020-12-04 2026-05-15 Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients Pembrolizumab, Pemetrexed, Oxaliplatin - Metastatic Colorectal Cancer Phase 1 Unknown NSABP Foundation Inc 33 2019-05-15 2022-06-10 Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer AE37 Peptide vaccine, Pembrolizumab - Triple-negative Breast Cancer Phase 2 Unknown NuGenerex Immuno-Oncology 29 2019-05-03 2021-06-02 Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer Letrozole, Palbociclib, Goserelin - Breast Cancer Phase 2 Completed NSABP Foundation Inc 24 2018-10-22 2022-04-20 Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status Trastuzumab, Cetuximab, Neratinib - Metastatic Colorectal Cancer Phase 2 Unknown NSABP Foundation Inc 35 2018-05-18 2022-03-31 Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer durvalumab - Rectal Cancer Phase 2 Completed NSABP Foundation Inc 45 2018-05-14 2022-04-20 Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling Doxorubicin, Cyclophosphamide, Weekly Paclitaxel - HER2-negative Breast Cancer Phase 2 Unknown NSABP Foundation Inc 64 2018-05-14 2023-03-06 Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo Placebo, Atezolizumab - Triple Negative Breast Cancer Phase 3 Active not recruiting NSABP Foundation Inc 1550 2017-12-19 2024-04-08 Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy durvalumab, Tremelimumab - Colorectal Cancer Metastatic Phase 2 Completed NSABP Foundation Inc 33 2017-07-31 2022-12-05 Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer Abemaciclib, Standard Adjuvant Endocrine Therapy - Breast Cancer Phase 3 Active not recruiting Eli Lilly and Company 5637 2017-07-12 2026-04-24 A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer Regorafenib, Placebo - Stage III (IIIB or IIIC) Colon Cancer Phase 3 Terminated NSABP Foundation Inc 34 2016-06-01 2022-04-14 PALbociclib CoLlaborative Adjuvant Study Palbociclib, Standard Adjuvant Endocrine Therapy - Breast Cancer Phase 3 Active not recruiting Alliance Foundation Trials, LLC. 5796 2015-08-01 2026-06-15 A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer Letrozole, palbociclib - Breast Cancer, Breast Carcinoma Phase 2 Completed NSABP Foundation Inc 307 2015-01-01 2022-01-13 Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer 5-FU, LV, ziv-aflibercept - Colorectal Cancer, Metastatic Colorectal Cancer Phase 2 Withdrawn NSABP Foundation Inc 2014-11-01 2014-12-02 A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer Neratinib, T-DM1 - Breast Cancer Phase 1 / Phase 2 Completed NSABP Foundation Inc 49 2014-08-01 2023-01-26
Showing 20 of 90. Sign in to see all of them.
Conditions studied Breast Neoplasms (54) · Colorectal Neoplasms (23) · Colonic Neoplasms (18) · Rectal Neoplasms (9) · Neoplasm Metastasis (4) · Triple Negative Breast Neoplasms (4) · Carcinoma, Intraductal, Noninfiltrating (3) · Fatigue (3) · Breast Carcinoma In Situ (2) · Breast Neoplasms, Male (2) · Carcinoma, Ductal, Breast (2) · Neoplasms (2) · Adenocarcinoma (1) · Adenomatous Polyps (1) · Breast Diseases (1)
Interventions Cyclophosphamide (18) · Doxorubicin (16) · Fluorouracil (13) · Paclitaxel (12) · Docetaxel (11) · Oxaliplatin (10) · Trastuzumab (10) · Bevacizumab (9) · Capecitabine (8) · Leucovorin (8) · Tamoxifen (7) · Radiotherapy (6) · neratinib (5) · Cetuximab (4) · Epirubicin (4)
Countries United States (75) · Canada (41) · Puerto Rico (14) · Ireland (11) · Spain (11) · United Kingdom (11) · Australia (10) · Belgium (9) · Germany (9) · Italy (9) · South Korea (9) · France (8) · Israel (7) · Austria (6) · Brazil (6)
Top investigators Norman Wolmark, MD (59) · James N. Ingle, MD (2) · Lori J. Pierce, MD (2) · Timothy J. Whelan, MD (2) · Alexander H Paterson, MD, FRCP (1) · Angela DeMichele, MD (1) · Boon Chua, MD (1) · Carla I. Falkson, MD (1) · Carmen J Allegra (1) · Clive S. Grant, MD (1) · Daniel F. Hayes, MD (1)
Results publications PMID 21880792 , PMID 21997132 , PMID 24077916 , PMID 38335467 , PMID 38979716 , PMID 10550154 , PMID 11098486 , PMID 12048273 , PMID 12149294 , PMID 12533263 , PMID 12636887 , PMID 12814333 , PMID 14559892 , PMID 15292384 , PMID 15621990 , PMID 15837984 , PMID 16236738 , PMID 16258083 , PMID 16606972 , PMID 16648506 , PMID 16754727 , PMID 16754728 , PMID 16945170 , PMID 17024757 , PMID 17264338 , PMID 17563856 , PMID 17851130 , PMID 18160686 , PMID 18302020 , PMID 18313521 , PMID 18332472 , PMID 18650156 , PMID 18650162 , PMID 18784962 , PMID 18824714 , PMID 19105706 , PMID 19213563 , PMID 19224552 , PMID 19231103 , PMID 19487378 , PMID 19730364 , PMID 20048179 , PMID 20133263 , PMID 20404000 , PMID 20519679 , PMID 20863759 , PMID 21079140 , PMID 21247310 , PMID 21768458 , PMID 21874312
NIH funding U10CA012027 (10), 2004 (1), 2005 (1), 2014 (1), 2016 (1), 2017 (1), U10CA021115 (1), U10CA023318 (1), U10CA025224 (1), U10CA032102 (1), U10CA180820 (1), U24CA075362 (1)